How effective is the treatment with Oplusituzumab/Ointuzumab (Besponsa)?

Olintuzumab/Olintuzumab (Besponsa) is a drug for adults Targeted drugs for pan>Bcell acute lymphoblastic leukemia (B-ALL) have shown significant therapeutic effects in clinical trials. This article will discuss in detail the therapeutic effect of oxinutuzumab/oxinutuzumab based on clinical experimental data.

B-ALLand treatment challenges:

B-ALL is a malignant form of leukemia that usually affects the development of lymphocytes. Especially for adult patients, traditional treatments are often not effective enough, or patients may develop relapse or drug resistance. This creates an urgent need to find more effective treatments.

Ogaintuzumab/OlintuzumabMechanism of action:

Olintuzumab/Olintuzumab is a monoclonal antibody drug whose main mechanism of action is to target the CD22 antigen on the surface of lymphocytes. CD22 is a specific marker for B cells. In B-ALL patients, leukemia cells usually express CD22. Ogaintozumab/Ointozumab binds to CD22 antigen, interfering with the normal functions of leukemia cells, including cell proliferation and survival, thereby reducing the number of leukemia cells.

Clinical trial data:

The following are some information aboutOplusituzumab/OlintuzumabKey clinical trial data on therapeutic efficacy:

1. INO-VATETrial: INO-VATE is an important clinical trial on oxinutuzumab/oxinutuzumab, studying the therapeutic effect of this drug on B-ALL patients. The trial included patients from multiple sites, some of whom had relapsed or refractory B-ALL. The results of the trial showed that more patients in the ogatinuzumab/ogatinuzumab treatment group achieved complete remission (Complete Remission, CR) and durable remission, the treatment group had a significantly longer relapse-free survival (Relapse-Free Survival, RFS) compared with the control group.

2. Long-term sustained remission: It is worth noting that the therapeutic effect of oxinutuzumab/oxinutuzumab is not only apparent in the short term, but can also last for a long time. In some patients, durable remission remains after treatment, providing patients with a longer chance of survival and better quality of life.

3. Safety: Clinical trial data also show that the safety profile of oxinutuzumab/oxinutuzumab is relatively good. While some patients may experience side effects such as nausea, fever, and infection, these side effects are usually manageable. In addition, compared with traditional chemotherapy, oxinutuzumab/oxinutuzumab has lower toxic side effects, especially damage to the liver and kidneys.

4. Pediatric patients: In addition, oxinutuzumab/oxinutuzumab also shows potential in pediatric B-ALL patients. Although studies have primarily focused on adult patients, some preliminary data suggest that oxinuximab may also have potential benefit in the treatment of B-ALL in children.

Ogaituzumab/Ointuzumab is an important treatment option that has demonstrated significant therapeutic effects in patients with B-ALL in clinical trials. This targeted drug is expected to improve the survival rate and quality of life of patients by interfering with the growth and survival of leukemia cells by targeting the CD22 antigen. However, treatment effectiveness varies based on individual patient differences and condition, so treatment requires a personalized plan based on each patient's specific circumstances. In conclusion, oxinutuzumab/oxinutuzumab represents an important advance in the field of leukemia treatment and provides new hope for B-ALL patients.

Ogaintozumab/Ointozumab has been launched in China, but it is not included in medical insurance. The domestic price is around 60,000 to 70,000 yuan, which is very expensive. Patients can buy it domestically. There are only original drugs available abroad, mainly Pfizer’s original drugs, which cost more than 80,000 yuan.

xa0